This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

Annual Report and Accounts for Year End March 2025

Message from our CEO ........................................................ 2 About STOPAIDS ................................................................. 3 USAID Dismantling & UK ODA Cuts ....................................... 5 Our Impact: Major Highlights ............................................... 6 People Over Profit ............................................................... 9 Quality of Life .................................................................... 11 Transforming Aid, Solidarity & Cooperation .......................... 14 Membership Engagement ................................................... 15 Anti‑Oppression Framework ............................................... 16 Hosting & Supporting Networks .......................................... 17 Looking Ahead to 2025/26 ................................................. 18 Our Staff .......................................................................... 19 Structure, Governance & Management ................................ 20 Financial Review ................................................................ 24 Independent Auditor’s Report ............................................. 26

and global health institutions at the World Health Assembly in May 2024.

Message from the CEO

At the start of this period it was clear to all that it would be a period of flux as a huge proportion of the democratic world was stepping up for elections. There was the potential for substantial change, but no one could guess quite how big that change would actually be.

The UK election at the start of July saw an end to 14 years of conservative rule with a large majority for a new Labour government. With this new government came hope for some substantive change tempered by the knowledge of a very challenged economy. For us at STOPAIDS based in the UK it meant of course a period of intense advocacy to engage new ministers and parliamentarians and influence the government’s future direction around development, health and HIV.

As this was happening, excitement was building following the successful trials of the groundbreaking new long-acting injectable medicine Lenacapavir. It was emerging as the closest thing the HIV movement has to a vaccine and presented a very real promise that, if we could make it accessible and affordable to everyone who needed it, it could catapult the HIV response towards the finish line. The end of AIDS as a public health threat could be a reality by 2030. This was the excitement at the International AIDS conference in July 2024 and it was this possibility that we aimed to attract the attention of UK and global political leaders as 2024 ended.

The start of 2025 stopped us all in our tracks. Most people knew that the outcome of the US election in November 2024 would have a big impact in the US and around the world, but few realised just how fundamentally it would alter global politics, financing and development. The decision of the US administration to gut USAID and stop PEPFAR programmes from one day to the next in January 2025 is still sending shock waves around the world and through millions of people’s lives. This has been compounded by a ripping up and redrawing of the global rules–based order and the undermining of multilateralism.

As we rounded out this period, the HIV and broader health responses were in chaos in many low- and middle-income countries and we were still trying to understand exactly what the immediate impact would be and what gaps were being left. There was exploration to see who could fill gaps and to identify what opportunities might be presented by the breaking down of the global system.

It was in the midst of this chaos that the UK and other donors decided to make their own dramatic ODA cuts. A devastating 40% cut by the UK government. This was a sad testament to a combination of pressures – US influence; rising populism and nationalism; a domestic economic black hole; consuming global conflicts; and a failure of the development sector to maintain a strong support base.

It is in this very difficult context that I am proud of the great work conducted by the STOPAIDS team to meet these challenges head on. With so much exciting possibility ahead at the start of this year it was hard to lose so much ground at home and abroad in such a short space of time. But the team has and will continue to rally with others in the UK and around the world to maintain and build progress, grounded in hope and determination.

Mike Podmore

ABOUT STOPAIDS

Our vision is a world without AIDS, where all people can realise their right to good health and wellbeing.

STOPAIDS is a UK-based HIV, health and human rights advocacy network made up of 70 organisations. We draw on our 35-year experience working on the HIV response to support UK and global movements that challenge the systemic barriers and inequalities that prevent people from realising their right to health and wellbeing.

Our strategy

We are now in the final year of our four-year strategic plan (2022-2025). The strategy’s overarching goal is for STOPAIDS to secure key steps towards transforming funding, power and systems, particularly for people living with and affected by HIV and marginalised populations. It focuses on three advocacy impact areas:

1. People over profit

Ensuring enhanced quality of life for people living with and affected by HIV
Transforming aid, solidarity and development co-operation

Action in each area is delivered through five key strategic approaches (as outlined in the infographic below) and is grounded in our Anti-Oppression Framework.

STOPAIDS’ Anti-Oppression Framework

Our work is framed by our living anti oppression framework aims to challenge and reverse problematic or oppressive logics and promote anti-oppressive values in our working practices.

The framework is grounded in four key values:

Humility: Ways of working that show self-restraint, but also ask you to reflect on your positionality, the power dynamics involved, and the value of / need for your contribution in an activity or setting.
Shifting power: Ways of working that not only seek to halt exploitative practices, but also address the cumulative disadvantages that exploitation has left behind by redistributing power.
Solidarity: Ways of working that ask you to take as many opportunities as possible to ‘spend’ your social capital or use your position / resources to challenge stigmas and the continued demonisation of certain people / groups.
Co-ownership: Ways of working that don’t presume the superiority of your approach and instead create opportunities to benefit from missing insights and skills by engaging in collective work.

STOPAIDS. STRATEGY DIAGRAM 2022-2025 VISION A.LS. It. STRATEGY GOAL OUR ROLE 'It W• • VK.b•i•d HIV. h••lth p fj-': Ja.or4¢y N¢wor on J5 ADVOCACY 114PACT AREAS AID. •OU0ATy AIIO IMVILQP•I•MT Cl>vQP••ATIQII: Ac(MJ to lov rol• ¢ob•l h ¢tyv•g• IVHC>. •nLI CMY•n• •hd Inn¥•ft¢• d•cldonffja&•rt Ifith•uKd glob•lly oh •thty•rhlp •Thd Oih•p k•y •rtn•rn Mo•t •nd •¥pp•rt •tylllw Influffi¢• ¢•l•brtll••. th• •41 publk ¢•mpal•Aln• ¢••vdln•t STRATEGIC APPROACHES ORGANISATIONAL FOUNDATIONS ANTI-OPPRESSION FRAMEWORK

The dismantling of USAID and cuts to UK ODA

Responding to the USAID cuts

Following the US stop work order issued on January 24th STOPAIDS became active in the UK and globally to map, highlight and mobilise to mitigate the impact of this decision on the HIV response and community and civil society partners.
In the UK, we convened our membership and partners across our work areas to engage the media, parliamentarians and the UK government. We developed multiple briefings and used multiple high-level opportunities to press the UK Government to step up global health leadership, including meetings with FCDO officials, Minister Annaliese Dodds, and Lord Fowler. STOPAIDS drafted a letter to the Prime Minister regarding the U.S. cuts to PEPFAR and the role that the UK might play in helping to avert the potentially devastating impact on people living with and affected by HIV. The letter was signed on by 38 civil society organisations from across the UK domestic and international sectors and was sent on 31st January.
At the global level we co-ordinated with the CHANGE group which was set up specifically around the US cuts and includes over 1000 people and mainly focused on HIV and health. We joined the co-ordination group and also co-led the UNAIDS sub-Working Group.
Over the course of the first half of the year it became clear that the chaos and immediate negative impact of the cuts was preventing many from having the time to think about the longer term implications and possibilities arising from the changes. We attended a roundtable of UK Global Health Leaders hosted by Wellcome and Gates with other UK-based key Global Health stakeholders to discuss the broader implications of these global changes. We then took the opportunity to have the first conversations with key partners to strategise around medium to long term changes that might be secured in global health architecture. It was from these discussions we developed a concept note and ultimately secured funding for a key piece of working for us in 2025 on Global Health Architecture reform.

Response to UK ODA Cuts Announcement

Not even a month passed after the US cuts before we need to also respond to the UK’s decision to reduce ODA to 0.3% of GNI by 2027. On 26th February STOPAIDS released a statement on its website and social media. In parallel we led the co-ordination of and sent a letter to the Prime Minister on 28th February from the members of the civil society working group on Global Fund and Gavi replenishments highlighting how the decision to cut will seriously undermine the ability of the UK to co-host effectively and to deliver a strong pledge.
We reached out to activists from other organisations (including Act Up London, One, Tax Justice UK and NAT) to plan a series of actions/stunts. On March 12th we mobilised 45 people to take part in the first public demonstration against the ODA cuts - a die-in in parliament square. The die-in got much-needed mainstream media attention in the printed Guardian and also in Politico’s newsletter.
Over the following few weeks we continued to co-ordinate with activist and campaigner groups to take further actions to counter the opinion that the UK public think the ODA cuts are a good idea. On March 26th we co-co-ordinated and spoke at a rally of several hundred people held by domestic and international organisations just prior to spring budget – drawing the links between the UK cuts to the poorest at home and abroad.

Te yc es Community protest on UK aid cuts March 2025 Se

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: People over Profit

A public-health driven model for researching and developing affordable, safe and effective health technologies for all

A key success this year was the inclusion of a commitment to “reformed incentive structures to drive innovation” within its NHS section of the Labour Party’s 2024 Manifesto, reflecting core recommendations from our manifesto briefing. The language aligned with our recommendations advocating for alternative innovation incentives, such as prizes, over extended patent monopolies and signaled a growing political recognition of the need to move beyond traditional patent-based models.
We elevated global visibility of the Lenacapavir access issue through coordinated advocacy, media engagement, and protest actions at AIDS 2024, resulting in widespread international media coverage. We also secured high-level UK political engagement, including parliamentary roundtables with Government CDO Ministers, speeches by key political figures, and direct inperson advocacy with the Prime Minister at his World AIDS Day Reception on the importance of Lenacapavir as a groundbreaking tool.
We raised the profile of access to dolutegravir by highlighting the implications of GSK’s lawsuit against the Colombian Government, securing MP engagement in Parliament on the issue.

Digital health technology and human rights

We strengthened collaboration with the World Health Organisation to advance gender, equity, and rights in digital health, influencing key global strategies and fostering sustained civil society engagement in digital health governance, and elevated Digital Health Rights Project (DHRP) research in key advocacy spaces.
We influenced the Global Digital Compact to embed key digital rights priorities, mental health, human rights, digital literacy, and a UN Digital Rights Advisory Service through sustained advocacy and meaningful youth engagement.
We elevated digital rights as a priority within the Global Fund, securing high-level commitments to integrate these issues into future agendas, strategy reviews, and technical guidance (which materialised in 2025)

International AIDS Conference 2024 F ,

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: Ensuring Enhanced Quality of Life for people living with and affected by HIV

Access to and funding for HIV services

We led a successful advocacy campaign which resulted in the UK Government’s pledge of £10 million to the Robert Carr Fund, surpassing both the fund’s ask and increasing from the previous UK contribution by 42%, marking it as a significant win.
Our ongoing advocacy on Global Fund replenishment led to a key success when the UK Government decided in February 2025 to co-host the replenishment with South Africa, demonstrating a clear signal of the UK’s renewed leadership on global health and international development.
We made key submissions to influence UK funding decisions for Unitaid, including to HM Treasury’s Spending Review survey and the Foreign Affairs Committee inquiry on soft power, highlighting Unitaid’s role in advancing UK global health leadership through partnerships with UK research institutions.
We helped secure a UK Government commitment to maintain its £8 million annual contribution to UNAIDS, safeguarding critical support amid ongoing ODA pressures.
Mobilised quickly to campaign against the UK’s decision to reduce ODA to 0.3% of GNI by 2027, issuing public statements, coordinating a civil society letter to the Prime Minister, and highlighting the implications for the UK’s role in Global Fund and Gavi replenishments. STOPAIDS co-founded and launched the Global Parliamentary Platform on HIV and AIDS at the International AIDS Conference with UNAIDS, Unite, Global Equality Caucus, Global TB Caucus and Waci Health – the networks brings together several hundred MPs from around the world to secure political and financial prioritisation of HIV.

Integration of HIV into broader physical and mental health discussions

In April 2024 we co-established the Health ImPACT Coalition with ITPC, WACI Health, GNP+, Frontline AIDS and GFAN, to ensure stronger civil society engagement in the UN Pact for the Future negotiations. It has over 300 member organisations.
In partnership with Key African CS partners we advocated for the inclusion of two indicators on the involvement of communities and civil society in GHI governance mechanisms at country and global level and percentage of GHI funding channelled to civil society and community-led organisations in the Draft Accountability Framework for the Lusaka Agenda.

Reduction of HIV-related structural barriers

Our advocacy, including meetings with the International Development Minister, parliamentary meetings and briefings coordinated with Ugandan partner Ark Wellness Hub for a House of Lords debate on Uganda’s Anti-Homosexuality Act all contributed to the decision of the UK Government to impose sanctions on 3 key Ugandan MP proponents of the law.

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: Transforming aid, solidarity and development co–operation

Sustainable Transition

STOPAIDS worked within the Developed Country NGO delegation to influence the Global Fund to approve a new 'global disease split' for 2026–2028 that better addresses underfunding in TB and malaria. Crucially, STOPAIDS helped secure strong Board support to safeguard funding for key and vulnerable populations through Catalytic Initiatives—ensuring continued investment in human rights, gender, and community-led responses across all replenishment scenarios.

Meaningful civil society and community involvement in global health governance

Through our role on the Global Fund Developed Country NGO Delegation, STOPAIDS influenced the Delegation’s statement ahead of the April Board meeting, advocating for the protection of Catalytic Investment funding, a critical review of sustainability and transition policies, and greater recognition of the limitations of GNI per capita in ensuring support for marginalised communities in middle-income countries.
We co-led a series of global consultations across civil society and communities on Community Leadership and Societal Enablers (in partnership with GNP+ and WACI Health), resulting in a comprehensive report that provides key recommendations to increase investment in communityled responses, expand civic space, support decriminalisation, and strengthen community-led monitoring.

Global Public Investment

Within our role on the steering committee of the Global Public Investment Network, we supported with the finalisation of the new GPIN strategy and the development of a campaign that seeks to position GPI as a key answer to sector reform in the wake of the huge ODA cuts.

Areas of work

People over profit

People must be put before profit. This is the only way to ensure every person can claim their right to good health and wellbeing, including marginalised populations. That’s why a huge focus of our advocacy efforts is on securing equal access to medicines, realising people’s digital health rights, and defining the private sector’s role in global health.

A community village protest at the 2024 International AIDS Conference in Munich

A public-health driven model for researching and developing affordable, safe and effective health technologies for all.

In early 2024 a key objective under this area of this work was to ensure that UK party Manifestos included policies to reform the pharmaceutical system, and advocate for a Public-health driven pharmaceutical R&D systems. We were pleased to see that the Labour Party’s 2024 Manifesto included a commitment to “reformed incentive structures to drive innovation” within its NHS section, reflecting core recommendations from our manifesto briefing. The language aligned with our recommendations advocating for alternative innovation incentives, such as prizes, over extended patent monopolies and signals a growing political recognition of the need to move beyond traditional patent-based models. Additionally, the Labour party framed public health driven R&D within the mission-oriented language in a report that we co-authored with Professor Mariana Mazzucato.

Over the next period the primary focus of our access work shifted to challenging the barriers to accessing new long-acting antiretrovirals (such as Lenacapavir) as well as access to Dolutegravir. On Lenacapavir, our work focused on building high-level political awareness and momentum behind efforts to expand access to Lenacapavir particularly through UK leadership and global cooperation. In July, we played a leading role in global advocacy efforts at AIDS 2024, supporting coordinated media engagement and protest actions that resulted in widespread international coverage including BBC, CNN, The Guardian, Bloomberg, and others raising the profile of the Lenacapavir access issue.

As we continued to push for strong parliamentary and government engagement on Lenacapavir, we saw success with our messaging cutting through. For example, in response to our question to International Development Minister Anneliese Dodds following her speech at Chatham House in October, she said that she had been briefed on the exciting possibilities of Lenacapavir as a significant innovation. In November we organised a parliamentary roundtable on lenacapavir which Lord Collins, Minister for Africa at the FCDO, attended alongside four Labour MPs including members of the APPG on HIV and AIDS. At the end of November our CEO attended the first World AIDS Day Reception to be held at No. 10 for over ten years. We inputted into the speech of UKCAB Co-ordinator Memory Sachikonye at the event and she highlighted the critical importance of Lenacapavir and funding for key global health institutions. Our CEO also spoke directly with the Prime Minister to stress the UK’s role in making the drug affordable and accessible worldwide.

We also worked to build awareness about the UK’s responsibility to challenge GSK’s lawsuit against the Colombian Government for issuing a Compulsory License to gain access to generic dolutegravir. We secured commitments from Dr Beccy Cooper MP to table parliamentary questions on the UK’s stance toward compulsory licensing, and from Jessica Toale MP to follow up on the Government’s position regarding the GSK lawsuit against Colombia. We also drafted a letter, at the request of The APPG on HIV, AIDS and Sexual Health, to the GSK CEO urging them to drop the case against the Colombian Government. Overall, we saw an uptick in political awareness, and we were encouraged by the fact that MPs were recognising the UK Government’s responsibility to engage on this issue.

Our CEO Mike Podmore and UNAIDS ED Winnie Byanyima at a World AIDS Day 2024 Reception held at Downing Street

Meaningful civil society involvement in design, implementation and governance of digital technologies and AI in health.

Our digital work continued through the Digital Health and Rights Project consortium we co-founded in 2019. This year we continued to play our role as Co-Chair of the Digital Health and Rights Project Advocacy working group, providing support and strategic guidance to consortium members. In May we attended the World Health Assembly, where we facilitated two preAssembly events on digital health and rights, increasing youth knowledge and engagement in digital health. We also built strategic relationships with IFMSA and the World Health Organisation (WHO) Youth Council, leading to invitations to high-level events and a panel speaking opportunity on global health governance.

We also hosted a WHA side event in collaboration with DTH-Lab. Speakers included the Minister of Innovation from Barbados, Meike Schleiff from WHO, Peggy Hicks from the OHCHR and young people from DHRP and DTH-Lab.

Throughout the year we continued to deepen our engagement with WHO, securing support to advance gender, equity, and rights in digital health. This included WHO referencing the DHRP report in a submission to the World Summit on the Information Society and acknowledging the need to address the digital gender divide and inclusion of marginalised groups. STOPAIDS played a key role in convening WHO departments for the first time on these issues and sustained commitments for future collaboration, including influence over the next Global Digital Health Strategy and Global Initiative on Digital Health. In early 2025 we led a civil society consultation with the WHO working group on AI ethics for health, resulting in stronger dialogue and interest from WHO in regular civil society engagement. Additionally, STOPAIDS secured WHO’s Head of Digital Health as a speaker for a high-level World Health Assembly side event, a key advocacy space for launching the upcoming DHRP research report (published in 2025).

We also continued to lead advocacy on digital rights within the Global Digital Compact (GDC), engaging with the FCDO, UN processes, and youth networks. We hosted a youth workshop and a roundtable with the UN Major Group for Children and Youth. Insights shared by young people during the workshop directly informed and strengthened our overall recommendations to the GDC process. Our sustained engagement, including at the UN General Assembly, influenced key outcomes in the final GDC text, notably the inclusion of mental health, the retention of human rights as a core principle, commitments to digital literacy, and the establishment of a UN-hosted Digital Rights Advisory Service. Looking forward we will focus on supporting national level advocacy to consider how to push for GDC to be implemented at the national level.

Our advocacy with the Global Fund gained strong traction, elevating digital rights as a priority issue. We led the development of and launched the Developed Country NGO Delegation’s report on digital health and rights at a well-attended Board webinar, cohosted with the Point 7 constituency and featuring key stakeholders like Unitaid and Germany. As a result, all three Board Committee leaders committed to supporting or considering the issue in future agendas. In April, a high-level in-person meeting in Geneva with the Global Fund deepened this engagement. The STOPAIDS CEO and Advocacy Co-Director met with IT and Human Rights teams, leading to commitments to involve us in the upcoming Digital Framework review and consider our input for technical guidance on human rights. Global Fund staff confirmed our work had sparked internal discussions and was already shaping their thinking on digital health and rights.

The Digital Health and Rights Project consortium Consortium Meeting in Cape Town, January 2025

Ensuring Enhanced Quality of Life for people living with and affected by HIV

STOPAIDS champions Quality of Life (QoL) in its broader sense. This means that we talk about three interconnected levels – HIVspecific components; health-related components: and the broader non-health specific well-being and wider social and economic aspects of quality of life. We need to consider QoL holistically and respond to the evidence accordingly with the necessary funding, programmes and legal reform.

Enhanced funding for and access to quality HIV prevention, treatment, care and support

For much of 2024 we’ve focused on highlighting the incredible opportunity created by long-acting injectables like Lenacapavir to catapult the global HIV response towards the finish line of ending AIDS by 2030. We highlighted this and the importance of ongoing leadership to the incoming UK government and made the case for increased UK funding for the global HIV response through key multilateral organisations including the Global Fund, Unitaid, UNAIDS, and the Robert Carr Fund. In early 2025 with the announcement coming from the US about the dismantling of USAID this work became even more important, and then with the subsequent UK government ODA cuts it became even more challenging.

In September 2024 we sent a letter to Minister Annaliese Dodds outlining ten recommendations for UK leadership on HIV globally, with a strong emphasis on multilateral investment. We also shared a tailored briefing with MPs to reinforce this message. In October, at a Chatham House event, our CEO raised a public question to Dodds on this issue, prompting her first public recognition of the importance of UK support for global health multilaterals.

At the No.10 HIV reception in November 2024, we saw a key success when the Prime Minister announced UK funding for a broader SRHR Grassroots Fund, which included a £10 million pledge to the Robert Carr Fund, matching the amount STOPAIDS had been campaigning for throughout the year. This is a £3 million (43%) increase from the 2021 pledge, exceeding the RCF’s own ask of £7 million and marking the first time the UK has significantly surpassed previous incremental increases. Achieved through sustained parliamentary pressure and close collaboration with FCDO officials, this was a major advocacy win for STOPAIDS. At the reception, the Prime Minister spoke about the essential work of other key institutions including The Global Fund to Fight AIDS, TB and Malaria; UNAIDS; and Unitaid which he recognised are fundamental to achieving our shared goal of ending AIDS as a public health threat by 2030. We worked with EJAF to ensure that the Prime Minister spoke with Global Fund ED Peter Sands and UNAIDS ED Winnie Byanyima and our CEO also had a chance to talk to him about the incredible opportunity that Lenacapavir presents.

The Unitaid UK Advocacy Working Group successfully strengthened parliamentary engagement and visibility for Unitaid. In November 2024, we convened a parliamentary roundtable titled “Breaking Barriers to Global HIV Medicines: Pathways to Ending the Epidemic.” The event was attended by parliamentarians, including Lord Collins, Minister for Africa, who delivered opening remarks, and MPs Emily Darlington, Flo Eshalomi, Taiwo Owatemi, and Martins Rhodes. This provided a valuable opportunity for MPs to gain insights into Unitaid’s unique contributions, such as its work in accelerating access to Lenacapavir, a key innovation in HIV treatment. The discussion also highlighted Unitaid’s previous successes, including its pivotal role in scaling up access to DTG (dolutegravir). This engagement not only deepened parliamentary understanding of critical barriers to global HIV medicine access but also reinforced Unitaid’s reputation as a leader in driving equitable health solutions.

In early 2025, we made key submissions to influence UK funding decisions for Unitaid, including to HM Treasury’s Spending Review survey and the Foreign Affairs Committee inquiry on soft power, highlighting Unitaid’s role in advancing UK global health leadership through partnerships with UK research institutions. A joint letter to the Prime Minister on the impact of ODA cuts further reinforced the message that Unitaid is a critical global health actor the UK must continue to support. Additionally, during British Science Week, STOPAIDS coordinated a parliamentary reception with the APPG on HIV, AIDS and Sexual Health, Scientists for Labour and the Parliamentary and Scientific Committee. The event, entitled ‘Under the theme Science and Partnership for an AIDSFree Generation: Adapting to a Changing World’, highlighted the power of science and innovation in the fight against HIV and explored how scientific progress – showcased through the long-acting technologies story – and strategic partnerships can expand access to life-saving treatments.

Throughout 2024 we continued to increase parliamentary pressure on the Government about the importance of a strong contribution to the GFATM from the UK Government and secured 36 parliamentarians to sign our letter to Keir Starmer for World AIDS Day calling for UK leadership on HIV globally, which included a call for co-hosting and a strong pledge. In February 2025 it was announced that the UK would co-host the Global Fund replenishment with South Africa. This decision to co-host was a major success and sent a signal that the UK were stepping up on the international stage to champion international development, health and the Global Fund. Following the announcement, we continued to increase parliamentary pressure on the Government about the importance of a strong contribution to the GFATM from the UK Government.

We also advocated for increased UK funding for UNAIDS, including direct briefings with key MPs, a letter to Minister Dodds ahead of a critical funding decision, and ongoing plans to raise UNAIDS' profile. Our advocacy, in particular the joint letter to the Prime Minister on the impact of the ODA cuts ahead of the UNAIDS business case review, helped to secure a commitment from the UK Government to maintain its £8 million annual contribution to UNAIDS and that it would deliver the same for the next year (this was partially contingent on reforms with respect to UNAIDS future operations).

Meaningful integration of HIV with and access to broader physical and mental health issues / UHC

In May 2024 STOPAIDS co-established the Health ImPACT Coalition with ITPC, WACI Health, GNP+, Frontline AIDS and GFAN, to ensure stronger civil society engagement in the UN Pact for the Future negotiations. The Coalition quickly increased its membership to more than 300 organisations. It provided Member States with written input into Rev 1 and 2 of the Pact for the Future to strengthen references to health, SRHR, human rights, and. communities. The final declaration included 13 references to health (an increase from 6 originally) and retained some key text on SRHR despite pressure to drop it. We also advocated for and secured some language around integrating human rights into regulative and norm-setting processes for new and emerging technologies.

In early 2025, the Health ImPACT Coalition agreed to continue its work to elevate health in global governance, responding to the limited focus on health in the Pact for the Future. The Coalition identified three core priorities for 2025: Exploring the creation of a UN Major Group on health; Fundraising and developing a governance structure; Engaging in key global processes, including the Fourth International Conference on Financing for Development, Second World Social Development Summit, UN High-Level Political Forum on the SDGs and COP30. STOPAIDS and ITPC represent the Coalition in a network of ImPACT Coalitions coordinated by the UN We Need, identifying ways to enhance collaboration through communication tools sharing relevant intel from global processes and negotiations, and ensuring the Coalitions are recognised and supported within the UN system. This work will continue over the course of the next year.

We also continued to track the ongoing work to implement the Lusaka Agenda and to discuss possible global mechanisms for taking forward discussions about the future of the global health architecture. We partnered with and supported leadership from African advocates in ensuring civil society actors were involved in all discussions on the Lusaka Agenda in Africa. We joined the Lusaka Agenda Future Arrangements sub working group that seeks to identify how discussions around the future global health architecture might be taken forward.

In February 2024 the Assembly of African Union Heads of State endorsed the establishment of an accountability mechanism to ensure the effective implementation of the Lusaka Agenda in Africa. In response, a Draft Accountability Framework was developed and Africa CDC in collaboration with the African Union Commission (AUC), African Constituency Bureau (ACB) and WACI Health are convening civil society to ensure their voices are reflected in the framework’s development and implementation. The framework includes 10 indicators and STOPAIDS provided feedback to add two indicators on the involvement of communities and civil society in GHI governance mechanisms at country and global level and percentage of GHI funding channelled to civil society and community-led organisations. We will continue to follow the progress of establishing the accountability framework.

The launch of the Global Parliamentary Platform on HIV and AIDS at the International AIDS Conference 2024

Reduction of HIV-related structural barriers

A key focus for us this year was on Uganda’s Anti-Homosexuality Act. Following two faceto-face meetings with the UK International Development Minister Andrew Mitchell in February and April, we held parliamentary meetings and wrote briefings coordinating with Ugandan partner Ark Wellness Hub. We contributed to a House of Lords debate on Uganda’s Anti-Homosexuality Act. This coordinated effort ultimately amounted to the UK Government imposing sanctions on key proponents of the law.

The founder and director of Ark Wellness Hub was also profiled in the Guardian, helping to build further awareness about the negative impact of the law in the national and global media.

At AIDS 2024, we strengthened our partnership with Ark Wellness Hub by cohosting a panel discussion on “Anti-LGBTQ+ Legislation and Violence in East Africa: How to Respond”, alongside the Robert Carr Fund Director Felicia Wong, Idris Mwendwa of HAPA Kenya, and the Global Fund.

For the latter half of 2024 and early 2025 we put this area of our work on hold due to capacity limitations.

Transforming aid, solidarity and development Co-operation

Through our work we seek to transform aid, solidarity and development co-operation. This means moving away from the outdated structures and practices of international aid that concentrate power in the hands of the few, toward an approach that is built on meaningful involvement of all stakeholders, particularly people living with and most affected by HIV.

Sustainable Transition

As a result of years of advocacy by STOPAIDS and the delegation, the Global Fund approved a 'global disease split' for 2026-2028 that will increase the weighting towards TB and Malaria if country allocation funds fall above £12 billion following replenishment. This recognised the historical underfunding of TB and challenges in the responses for both TB and Malaria, while also recognising the essential programming costs for HIV.

While this is a positive move for the TB response, which is closely related to the HIV response, there are potential risks for key and vulnerable populations (KVPs) in middle – income countries, especially as the GF is also driving more funding to LICs (given the deteriorating economic capacity) and potentially faces a relatively lower or similar replenishment for its next allocation period. STOPAIDS supported the delegation to consistently highlight the concerns for KVPs, which also received support from many other constituencies. As a result, there was strong Board agreement that Catalytic Initiatives should be included in all replenishment scenarios put forward and that this would include a substantial amount for human rights and gender, and community networks & engagement.

Meaningful civil society and community involvement in global health governance

We continued to use our seat on the Global Fund Developed Country NGO delegation to advocate for our approach to the Allocation Methodology, Sustainability and the Eligibility Policies. This helped build the knowledge of delegation members on issues such as the weaknesses of relying on GNI per capita and to highlight how the delegation has protected funding for the most marginalised in middleincome countries. This influenced the Delegation’s statement ahead of the April Global Fund Board meeting, through which we pushed for funding for Catalytic Investments to be protected, a close review on the sustainability and transition parts of the STC policy and importance of recognising the limitations of GNIpc. These discussions will continue into 2025. Additionally, we supported the Delegation in overseeing a research consultancy on the Global Fund’s approach to digital health and rights, contributing to evidence generation and to build momentum on this issue.

Between July and October 2024 STOPAIDS, in partnership with the love Alliance Partnership, WACI Health and GNP+, led a series of consultation meetings on Community Leadership and Societal Enablers (CLSE) focused in three key areas: Policies, programmes, and investment in community leadership and societal enablers; Barriers to investing in & scaling up community-led responses & societal enablers; and Accountability for financial investments in community leadership, community systems and societal enablers.

Following these consultations, we prepared a report that captured key insights and recommendations to increase investment in community-led responses, expand civic space, support decriminalisation, and strengthen community-led monitoring. The report identified barriers to aligning global targets with local action and outlines strategies to scale up societal enabler programmes. These recommendations will inform a forthcoming white paper and advocacy roadmap led by the O’Neill Institute due to be published in 2025.

Global Public Investment

As Our CEO has continued to serve on the Steering Committee of the Global Public Investment Network (GPIN) and has played an active role in the working group guiding the development of GPIN’s new strategy. We also continued to co-chair the Global Health Working Group of GPIN.

This year with the new Labour government reviewing its international development priorities marked an important opportunity to promote Global Public Investment (GPI) as a key idea. The GPIN secretariat, with support from the STOPAIDS CEO, submitted a proposal to the International Development Select Committee as a potential inquiry topic.

For most of this year the focus has been finalising the new GPIN strategy and, particularly since the announcement of the USAID cuts, the development of a campaign that seeks to position GPI as a key answer, alongside other structural responses such as debt cancellation and tax reform, to the reform needed in the global development architecture.

Membership Engagement

The aim of our membership engagement work is to ensure the growth and sustainability of our membership network and share knowledge and best practice to further our common goals. This includes ensuring diverse and relevant opportunities so that a broad range of members can engage and collaborate on activities to further our common goals and objectives.

Member meetings are a key opportunity for members to engage with the network on different thematic topics. In June 2024 we held a meeting which featured presentations from Frontline AIDS and AfGH on Ethical Fundraising Policies, sparking valuable discussion among members.

In February 2025 we convened members to discuss the news coming out of the US in relation to the shut down of USAID and the stop work order, particularly tracking the impact on PEPFAR cuts and the impact of all of this on people living with and affected by HIV globally. We used this meeting to discuss what we could do as a network, share updates, resources and discuss collective actions. Later that month we convened members again to discuss the UK government’s announcement to cut ODA. In the immediate period after these announcements, we coordinated advocacy with members on these cuts.

In March two new organisations joined the network in March: AIDS Healthcare Foundation, and the NCD Alliance through a reciprocal membership arrangement.

Anti-Oppression Framework

Our anti-oppression framework is a new and significant undertaking for us as an organisation and has had a huge impact on how we work and how we hold ourselves and others to account. The framework is primarily centered around challenging and reversing problematic practices or oppressive logics that need to be undone and promoting anti-oppressive values.

The five key values of the framework are:

Humility, ways of working that show self-restraint but also ask you to reflect on your positionality, the power dynamics involved, and the value of / need for your contribution in an activity or setting;

Shifting Power, ways of working that seek to halt exploitative practices and address the cumulative disadvantages that exploitation has left behind by redistributing power;
Solidarity, ways of working that ask you to take as many opportunities as possible to ‘spend’ your social capital or use your position/resources to challenge stigmas and the continued demonisation of certain people/groups;
Co-ownership, ways of working that don’t presume the superiority of your approach and instead create opportunities to benefit from missing insights and skills by engaging in collective work;
and the meaningful engagement of people living with and affected by HIV and other health conditions, ways of working that ensure that the voice and perspectives of those with lived experiences informs every aspect of what we do.

We have been implementing the anti-oppression framework over the last 3 years. For all areas of es ee our work we regularly report to our Board of how our actions are aligned to our anti-oppressive principles. We conduct anti-oppressive ‘experiments’ and document the key learnings and challenges that these experiments thrown up.

A couple of examples of these experiments in action include:

Consulting community-led organisations about campaigns we’ve been invited to get behind: [c em So When we’ve been approached by other partners in the sector (who are not community-led organisations) to sign a letter and or get behind a particular ask for a campaign we have consulted with community-led organisations before adding our organisational support. This is to ensure a campaign has the backing of the communities it is seeking to serve and is informed by their perspectives. A , mg heme Collaborate with and reference perspectives of people with lived experience of health inequities:

On a government inquiry into how the FCDO works with civil society in aid recipient countries, ND The ex @e= rather than writing the submission ourselves - which we do not have the legitimacy to do, being an advocacy organisation based in the UK - we collaborated with and referenced work from activists from and based in the global South.

Hosting and supporting networks to improve 20 collaboration and coordination

As a member-based convening network, STOPAIDS knows the value of support and facilitation, particularly for smaller organisations. Our contributions to global health and the HIV response are not just evidenced through our advocacy efforts but also our organisational structure.

STOPAIDS supports organisations/ groups in the global public health space to achieve their goals by hosting their staff and/or providing governance, financial administration and project support services. This back-office support gives the institutional framework necessary for smaller organisations to exist and work without registering as separate legal entities- which is not always possible for smaller organisations from a capacity and resource standpoint.

In 2024-25 STOPAIDS hosted or supported:

Action For Global Health: A UK advocacy network of five staff with 55 member organisations focused on global health. STOPAIDS holds AFGH’s funding, employs its staff and provides back-office support.
Students For Global Health: A network of global health student campaigners in the UK. STOPAIDS holds SGH’s funding, provides back-office support and employs its coordinator who is managed by the Action for Global Health.
All Party Parliamentary Group (APPG) on HIV & AIDS: STOPAIDS employs the coordinator and provides the APPG with an annual grant.
UNITAID Board NGO Delegation: STOPAIDS holds the delegation grant and employs the UNITAID NGO Delegation communication focal point. We have also provided fundraising support to the Board members.
Global Network of People Living with HIV (GNP+): STOPAIDS have an agreement with GNP+ to employ one GNP+ staff member, based in the UK.
Paediatric Adolescent Treatment Africa (PATA): STOPAIDS has an agreement with PATA on behalf of the Coalition for Children Affected to employ one staff member, based in the UK

Looking forward: Our plans for 2025/26

People Over Profit

In 2025-26 we will continue to co-ordinate the Missing Medicines coalition and engage on ensuring Lenacapavir is affordable and accessible. A key focus will be securing funding to support this work.

Our digital health and rights work will focus on driving progress toward universal digital inclusion, ensuring young adults and marginalised communities can reliably access and benefit from digital technologies. We will work towards strengthening protections against technologyfacilitated abuse, advocating for policies and systems that uphold privacy, safety and security, and guarantee that human rights are protected online as they are offline.

Ensuring Enhanced Quality of Life for people living with and affected by HIV

Following the announcement of UK cuts to ODA, a key focus will be influencing through media and parliamentarians and engaging directly with the UK government to ensure prioritisation of HIV politically and financially as well as broader health. This will mean advocacy to limit the impact of possible cuts on global health and HIV as much as possible. It will also mean making a strong case for HIV as one of the best examples of the power and impact of international development and highlighting the inspirational possibility of ending AIDS by 2030 created by lenacapavir. One key area for development is to work closely with the domestic HIV charities to draw links between the domestic and international HIV responses.

We will continue to convene UK civil society to advocate for strengthened UK leadership as a cohost of the Global Fund replenishment and that the UK delivers a pledge of at least £1 billion at the 8th replenishment. We will also strengthen political commitment and resources for Unitaid and reinforce civil society partnerships to amplify joint advocacy, expand strategic communications to raise awareness of Unitaid’s value. At the same time we will also make the case for the critical role and needed UK support for two other critical institutions for the global HIV response – UNAIDS and Robert Carr Network Fund.

At the global level we will also continue to foster the growth and activities of The Global Parliamentary Platform on HIV and AIDS, which we co-founded with other key parliamentary networks. We will also seek to source some funding to enable us to develop the Health Impact Coalition so that it has a diverse and representative governance mechanism and more staff capacity to drive forward advocacy opportunities to represent health within non-health specific processes.

Transforming aid, solidarity and development co-operation

In the context of ODA cuts and chaos across global development, STOPAIDS will reach out and collaborate with partners to develop a project that will fill a gap in discussion among civil society and communities around what the future of the global health architecture should be. It will be ideal if we can secure some funding to support this but we will do it anyway. We will also utilise our experience and leadership in global health governance to try to ensure strong participation of civil society and communities in all multi-stakeholder discussion and decision-making that happens around the future of the global health architecture.

The key focus for the Global Public Investment Network will be to promote global public investment across the numerous processes emerging to discuss the future of the development and financial architecture and secure member state support, particularly from low and middleincome countries. STOPAIDS’ role will be primarily in ensuring good governance of the network and ensuring there is a strong strategy and sufficient staff capacity to implement it during this critical year.

STOPAIDS Team

Mike Podmore, Chief Executive Officer

Siomha Cunniffe, Director of Development and Engagement

Simon Bowkett, Director of Development and Engagement (maternity cover) - left October 2024

Saoirse Fitzpatrick, Co-Director of Advocacy - left August 2025

Tabitha Ha, Co-Director of Advocacy

Courtenay Howe, Advocacy Manager

Nicole Woods, Finance Manager

Vivienne Price, Team Coordinator

Molly Pugh Jones, Advocacy Manager

Molly Thompson, NGO Delegation Liaison Officer (UNITAID Board) / Senior Advocacy Advisor (STOPAIDS) Amina Babirye, Senior Advocacy Advisor

Olivia Compton, Senior Communications and Community Engagement Advisor – left June 2024

Jake Atkinson, Campaigns and Media Advisor – left September 2024

Louis Pilard, Media and Communications Manager – started October 2025

Sara Woodward, Finance Administrator – started October 2025

Structure, governance and management

TRUSTEES

David Adams, Frontline Aids

Katherine Kirk Arie, Results UK

STOPAIDS is a company limited by guarantee, registered in England no. 2589198, and is UK registered charity No. 1113204.

REGISTERED OFFICE:

Yael Azgad

167-169 Great Portland St, London W1W 5PF, United Kingdom

Patricia Cassidy, Chair, mothers2mothers

Colleen Daniels, Harm Reduction International (resigned March 2025)

Husseina Hamza, Red Ribbon Living Well

Victoria Howard, MSI (resigned July 2024)

AUDITORS

Wenn Townsend, 30 St Giles, Oxford OX1 3LE

BANKERS

THE CO-OPERATIVE BANK PO Box 101, 1 Balloon Street, Manchester M60 4EP

Rosemary Mburu, WACI Health

Fionnuala Murphy, Frontline AIDS (resigned April 2024)

PRINCIPAL OFFICERS

Michael Podmore (Chief Executive Officer)

Maria-Louise Rosbech, Global Justice Now

Kate Thompson (appointed December 2024, resigned July 2025)

Siomha Cunniffe (Director of Development and Engagement)

The directors of the charitable company are its trustees for the purpose of charity law and the members of the company limited by guarantee. Throughout this report they are collectively referred to as the Trustees or the Board of Trustees.

All trustees served for the full year unless otherwise indicated above. None had any beneficial interest in the charity and no remuneration of trustees/ directors is paid by the charity.

The trustees are pleased to present their report together with the audited financial statements of the charity for the year ended 31 March 2025.

Governing Document

STOPAIDS is a charitable company limited by guarantee, incorporated on 6 March 1991 and registered as a charity on 19 March 2006, it changed its name from The UK Consortium on AIDS and International Development on 5th September 2013. The company was established under a Memorandum of Association which established the objectives and powers of the charitable company and is governed under its Articles of Association. These Articles were updated by members on 22nd January 2014.

Organisational Structure

The Board of Trustees can have up to 12 members. It meets every three months and is responsible for the strategic direction, policy and overall governance of the charity. Members of the Board of Trustees, 10 members of which must be nominated from Member Organisations of STOPAIDS and two of which must be living with HIV, are elected to serve for a period of three years. They may stand for re-election once, serving for a maximum of six years, after which they must stand down for at least one year. Once a Trustee has been elected to the Board, they meet with the Board Chair, the CEO and the Director of Development and Engagement for an induction session. They are also introduced to the team and provided with an overview of each team member's role. As part of the induction new Trustees are provided with a term of reference outlining the role, main responsibilities and tasks of the board and details about appointment and eligibility of board members, term of office, meetings and expectations of Trustees. Trustees are required to review and sign the Trustee Terms of Reference. They are also provided with the following documents: The Charity Commission's Essential Trustee Guide, STOPAIDS's governing documents, the most recent annual report and accounts, the organisational strategy, an organisational chart and an overview of the board subcommittees.

Trustees operate four sub-committees: Fundraising and Membership, Risk, Finance and Human Resources. A minimum of 2 trustees sit on each sub-committee.

Day to day running and management, including financial management of STOPAIDS office and activities is the responsibility of the Secretariat, led by the CEO.

The Directors who held office during the year are listed under reference and administrative details above.

Key Management Personnel Remuneration

The Trustees consider the Board of Trustees, the CEO and the senior leadership team as comprising the key management personnel of the charity in charge of directing and controlling the charity and running and operating the charity on a day-to-day basis. All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses and related party transactions are disclosed in note 4 to the accounts.

Trustees are required to disclose all relevant interests and in accordance with the Trust’s policy withdraw from decisions where a conflict of interest arises.

The pay of the CEO and senior leadership team is reviewed annually and is normally increased in line with our pay policy. The remuneration is reviewed to ensure that it is commensurate with similar roles.

Risk Management

The Trustees review the risks the charity faces at every Trustee meeting. The Risk Log for the organization continued to assess the low, medium, and high risks posed to the organisation and ensured discussion at the Board of priority actions to mitigate high risks.

During the year risk management focused heavily on cuts in funding and resource mobilisation for the HIV sector and the international development/ global public health sector.

Fundraising standards information

Members of the Charity’s fundraising department organise events and carry out fundraising activities to generate funds for the charity. The Charity does not use professional fundraisers or commercial participants. There have been no complaints about fundraising activity this year. The charity has signed up to the Fundraising Regulator’s Code of Fundraising Practice. All the charity’s marketing activities are undertaken directly to ensure that it is not unreasonably persistent or intrusive. Direct marketing materials contain clear details of how to unsubscribe to future communications and care is taken to limit the level of communications being sent out.

OBJECTIVES AND ACTIVITIES

THE RELIEF OF SICKNESS, AND THE PRESERVATION AND PROTECTION OF GOOD HEALTH OF

PEOPLE LIVING WITH HIV AND AIDS OR AT RISK OF HIV TRANSMISSION IN DEVELOPING

COUNTRIES BY, IN PARTICULAR BUT NOT EXCLUSIVELY:

PROVIDING A FORUM FOR THE EXCHANGE OF INFORMATION AMONG AND BETWEEN NONGOVERNMENTAL BODIES
LIAISING WITH GOVERNMENTAL AND INTERNATIONAL BODIES; AND
EDUCATION OF THE PUBLIC ON HIV AND AIDS AND THE WORK OF NON-GOVERNMENTAL BODIES IN THE FIELD.

Public Benefit Statement:

Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing aims and objectives and planning future activities. Our direct beneficiaries of STOPAIDS are our member organisations and the organisations and groups that we host. However, the ultimate beneficiaries of all of our work are global population of people living with and affected by HIV and AIDS who are supported by our members and by the domestic and international STOPAIDS advocacy efforts and the technical support and advice we provide to the UK government and multilaterals on their role in the global HIV and broader global health inequity response.

Financial review

The Trustees are pleased with the financial performance this year, particularly considering the substantial economic challenges that occurred this year, including huge ODA cuts, and its impact to our funding streams. We have worked hard and continued strong relationships with funders and secured new sources of income whilst maintaining the backing and trust of our members, without whose financial and time contributions STOPAIDS would not thrive as a convening and advocating network.

STOPAIDS has continued its role of hosting staff from other organisations working to similar objectives as STOPAIDS. This allows us to facilitate and support their work by managing employment contracts and back end financial and administrative office support at an overhead fee of 10-15% of the costs involved. As well as providing an essential service to other organisations without the capacity to function as separate legal entities, this allows economies of scale to further the efficiency of our operations.

Income for this period was £1,256,976 (£1,443,529 in 2023-24). This includes restricted funds from grant making trusts of 1,028,384 (compared to £1,128,180 in 2023-24). Monies from membership fees accounted for 8.9% of total income (8.3% the previous year).

Total expenditure for this period was 1,385,690 (£1,479,597 in 2023-24). Our income and expenditure decreased slightly this year due to a couple of factors. We stopped hosting roles for GNP+ during the year so there was a reduction of both income and expenditure generated by our hosting role. There was also a reduction in our staffing costs with some staff leaving and not being immediately replaced. There was a deficit for the year of £128,714 (deficit of £36,068 in 2023-24), giving total funds of £315,547, of which £194,356 is unrestricted and £121,191 is restricted.

At the end of the year the charity remains in a healthy financial position and the trustees consider this to be a satisfactory result, particularly considering funding cuts experienced by many member organisations. It was a strong vote of support that members demonstrated their continued commitment to STOPAIDS through continued payment of membership fees. The charity will continue to closely review financial performance on a regular basis to ensure actual income and expenditure is in line with budget. There will be particular focus on income generation and diversifying sources of income to maintain this healthy position.

Reserves

It is the policy of STOPAIDS to maintain a reserves level to ensure delivery of core goals in line with the STOPAIDS Strategy. The trustees wish to ensure adequate reserves to mitigate any risks. Our general reserves fund policy is a minimum of 3 months operating costs (£160,801) and up to 9 months operating costs (£482,403). Our reserves policy does not include the running costs for hosted organisations; these funds are ringfenced in our restricted funds. Maintaining reserves at this level will ensure resilience against foreign exchange fluctuations, changes in membership funding and any other unanticipated impact of political changes and ensure that STOPAIDS can meet its legal obligations as an employer should be we cease to be a going concern/ experience a significant adverse event to our funding stream. The trustees review the policy against the Risk Register on a regular basis.

During the year our reserves, shown on the balance sheet as unrestricted funds have decreased to £192,476 (£209,777 in 2023-24), which are within the desired range as detailed above, however Trustees are working on a longer term goal of increasing reserves to a higher point in this range to further protect against risk.

The Statement of trustees’ responsibilities

The Trustees (who are also directors of STOPAIDS the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

select suitable accounting policies and then apply them consistently;

observe the methods and principles in the Charities SORP 2019 (FRS 102);
make judgements and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the Trustees are aware:

there is no relevant audit information of which the charitable company’s auditor is unaware; and
the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared having taken advantage of the small companies’ exemption in the Companies Act 2006.

The accounts were approved on the 12th November 2025 and signed by:

==> picture [125 x 49] intentionally omitted <==

Trustee

Chair, Patricia Cassidy

Independent Auditor’s Report to the members of STOPAIDS

Opinion

We have audited the financial statements of STOPAIDS (the ‘charitable company’) for the year ended 31 March 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the charitable company’s affairs as at 31 March 2025, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees’ report (incorporating the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the directors’ report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors’ remuneration specified by law are not made; or

Independent Auditors’ Report to the members of STOPAIDS (continued)

Matters on which we are required to report by exception (continued)

we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies’ regime and take advantage of the small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 29, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

Enquiry of management, those charged with governance and the entity’s solicitors around actual and potential litigation and claims;
Reviewing minutes of meetings of those charged with governance;
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;
Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

...........................................

Benjamin Hayes BSc FCA (Senior Statutory Auditor) For and on behalf of Wenn Townsend Chartered Accountants and Statutory Auditor 30 St Giles Oxford OX1 3LE

12[th] November 2025

STOPAIDS

Statement of Financial Activities (including Income and Expenditure Account) for the year ended 31 March 2025

==> picture [506 x 354] intentionally omitted <==

----- Start of picture text -----
||||||| |---|---|---|---|---|---| |2025|2025|2025|2024| |Notes|Unrestricted|Restricted|Total|Total| |£|£|£|£| |Income| |Contributions from members and observers|23,650|88,089|111,739|119,934| |Grants and contracts|3a|89,587|1,028,384|1,117,971|1,247,910| |Donations received|1,138|-|1,138|4,799| |Other income|3b|21,252|-|21,252|67,377| |Interest income|4,876|-|4,876|3,509| |───────|─────── ─────── ───────| |Total|140,503|1,116,473|1,256,976|1,443,529| |───────|─────── ─────── ───────| |Expenditure on:| |Raising funds|1,200|-|1,200|330| |Charitable activities|4|158,454|1,226,036|1,384,490|1,479,267| |───────|─────── ─────── ───────| |Total|159,454|1,226,036|1,385,690|1,479,597| |───────|─────── ─────── ───────| |Net income/(expenditure)|(19,151)|(109,563)|(128,714)|(36,068)| |───────|─────── ─────── ───────| |Transfers between funds|10|401|(401)|-|-| |───────|─────── ─────── ───────| |Net movement in funds|(18,750)|(109,964)|(128,714)|(36,068)| |───────|─────── ─────── ───────| |Reconciliation of funds| |Total funds brought forward|213,106|231,155|444,261|480,329| |───────|─────── ─────── ───────| |Total funds carried forward|10|194,356|121,191|315,547|444,261| |═══════|═══════ ═══════ ═══════|

----- End of picture text -----

The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities.

STOPAIDS

Balance Sheet As at 31 March 2025

		2025	2024
	Notes	£	£
Fixed assets
Tangible fixed assets	7	1,880	3,329
Current assets
Debtors	8	103,960	270,972
Cash at bank and in hand		824,989	496,893
		───────	───────
		928,949	767,865
		───────	───────
Creditors:amounts falling due within one year	9	(615,282)	(326,933)
		───────	───────
Net current assets		313,667	440,932
		───────	───────
Net assets		315,547	444,261
		───────	───────
Funds
Unrestricted funds		194,356	213,106
Restricted funds		121,191	231,155
		───────	───────
Total funds	10	315,547	444,261
		═══════	═══════

The financial statements have been prepared in accordance with provisions applicable to companies subject to the small companies’ regime.

Approved and signed on behalf of the Executive Committee on 12[th] November 2025

==> picture [122 x 60] intentionally omitted <==

……………………………………. Patricia Cassidy – Chair of Trustees Company number 02589198

STOPAIDS

Statement of Cash Flows for the year ended 31 March 2025

		2025	2024
	Notes	£	£
Cash flow from operating activities	12	328,096	(177,303)
Cash flow from investing activities
Purchase of tangible fixed assets		-	(2,538)
		───────	───────
Increase in cash and cash equivalents for the year		328,096	(179,841)
Cash and cash equivalents at the beginning of the year		496,893	676,734
		───────	───────
Total cash and cash equivalents at the end of the year		824,989	496,893
		═══════	═══════

STOPAIDS

Notes to the accounts for the year ended 31 March 2025

1. General information and basis of preparation

STOPAIDS is a charitable company limited by guarantee in England and Wales. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information in these financial statements. The nature of the charity’s operations and principal activities are detailed in the Trustees Report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

2. (a) Basis of accounting

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

(b) Fund accounting

(i) The unrestricted funds are available for use at the discretion of the trustees in furtherance of the objectives of the charity.
(ii) Designated funds are unrestricted funds earmarked by the Executive Committee for particular purposes.
(iii) Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal.

A final review of the allocation of expenditure is performed after a project or contract has been completed, which can give rise to a transfer between funds.

(c) Income

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

(i) Income from grants, donations and gifts is included in full in the Statement of Financial Activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the Charity, are recognised when the charity becomes unconditionally entitled to.
(ii) Donated services and facilities are included at the value to the charity where this can be quantified.
(iii) The value of services provided by volunteers has not been included in these accounts.
(iv) Investment income arises from interest receivable on funds held in interest bearing bank accounts and is included when receivable.
(v) Income from charitable trading activity is accounting for when earned.

(d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

(i) Expenditure on raising funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes.
(ii) Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

(d) Expenditure (continued)

(iii) Other expenditure included governance costs, those costs associated with meeting the constitutional and statutory requirements of the charity and include the auditor’s fees and costs linked to the strategic management of the charity and support costs.
(iv) All costs are allocated between the expenditure categories of the SOFA on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned on an appropriate basis.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. The analysis of these costs is included in note 4.

(e) Fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life, which is typically applied at 33% per annum on the straight line method. Only items costing over £1,000 are capitalised.

(f) Foreign currency

Transactions in foreign currencies are initially recorded in the entity’s functional currency, which is pound sterling, by applying the spot exchange rate on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. All differences are taken to the Statement of Financial Activities.

(g) Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

(h) Impairment

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset’s cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

(i) Leases

Rentals payable and receivable under operating leases are charged to the SoFA on a straight line basis over the period of the lease.

(j) Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

(k) Tax

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

(l) Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

3a. Income from grants and contracts

==> picture [466 x 445] intentionally omitted <==

----- Start of picture text -----
|||||||| |---|---|---|---|---|---|---| |Total|Total| |Core|Hosting|Advocacy|Other|2025|2024| |£|£| |Restricted Grants| |WACI Health|-|-|-|-|-|62,337| |HRI (CSA sub-grant)|-|-|13,107|-|13,107|18,148| |APPGA|-|30,966|-|-|30,966|40,855| |Botnar Foundation|-|-|204,307|-|204,307|181,225| |GNP+|-|43,692|-|-|43,692|96,522| |GNP+ (Love Alliance DH)|-|-|-|-|-|35,764| |Joseph Rowntree Ch Trust|-|-|-|-|-|5,074| |Aidsfonds (Love Alliance)|-|-|-|-|-|5,737| |New Venture Fund Phase III|-|-|-|-|-|10,577| |New Venture Fund Phase IV|-|-|114,997|-|114,997|60,611| |UNITAID|-|114,741|30,208|-|144,949|200,919| |PATA|-|138,687|-|-|138,687|99,251| |Aidsfonds (CLSE)|-|-|47,983|-|47,983|-| |HCAI|-|-|-|-|-|31,151| |The Bill and Melinda Gates| |Foundation (AfGH)|-|-|195,135|-|195,135|275,704| |Restless Development| |(GenEndIt Campaign)|-|-|-|-|-|4,305| |Warwick Policy Support|-|-|19,791|-|19,791|-| |Unitaid 2024-26|-|-|40,043|-|40,043|-| |The Eleanor Crook| |Foundation (AfGH)|-|-|28,233|-|28,233|-| |Ronald W. Naito| |Foundation (AfGH)|-|-|6,494|-|6,494|-| |─────── ───────|─────── ─────── ─────── ───────| |-|328,086|700,298|-|1,028,384|1,128,180| |─────── ───────|─────── ─────── ─────── ───────| |Unrestricted grants| |JOFFE|50,000|-|-|-|50,000|25,000| |Other|39,587|-|-|-|39,587|94,730| |─────── ───────|─────── ─────── ─────── ───────| |89,587|-|-|-|89,587|119,730| |─────── ───────|─────── ─────── ─────── ───────| |89,587|328,086|700,298|-|1,117,971|1,247,910| |═══════ ═══════|═══════ ═══════ ═══════ ═══════|

----- End of picture text -----

During the year STOPAIDS received the following grants:

==> picture [465 x 137] intentionally omitted <==

----- Start of picture text -----
|||||||| |---|---|---|---|---|---|---| |Grant|Purpose of Grant| |HRI (CSA sub-grant)|To support the effective functioning of the Civil| |Society Alliance for Human Rights in the Pandemic| |Treaty (CSA) and its advisory group; and to| |support CSA members to engage in the Pandemic| |Treaty process| |All Party Parliamentary Groups on Aids (APPGA)|Reimbursement of salary for the Policy Advisor of the| |All Party Parliamentary Group on HIV and AIDS| |administered by STOPAIDS| |Botnar Foundation|Digital rights and health project for Botnar Foundation| |Global Network of People Living with HIV (GNP+)|Reimbursement|of|salary|for|Staff|GNP+| |administered by STOPAIDS|

----- End of picture text -----

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

3a. Income from grants and contracts (continued)

Grant	Purpose of Grant
New Venture Fund	To enable STOPAIDS to engage in high profile advocacy in an attempt to increase the UK government’s pledge to the Global Fund at the next replenishment
UNITAID	To support the activities for the NGO delegation for the UNITAID Board
PATA	Reimbursement of salary for staff PATA administered by STOPAIDS
Aidsfonds (CLSE)	To support the Community Leadership and Societal Enablers Consultative Process
The Bill and Melinda Gates Foundation (AfGH)	To support Action for Global Health
Warwick Policy Support	Enhancing the Global Fund’s approach to digital technologies to advance the health and rights of marginalised communities in low- and middle-income countries
Unitaid 2024-26	Mobilising UK support for Unitaid
The Eleanor Crook Foundation(AfGH)	To support core costs for AfGH
Ronald W. Naito Foundation (AfGH)	To support AfGH to expand and catalyse their health equity and climate advocacy across their four interconnected strategic priorities

3b. Other income

Other income
			Total	Total
	Unrestricted	Restricted	2025	2024
	£	£	£	£
Hosting fees	17,350	-	17,350	19,577
Contributions to events/roles	3,902	-	3,902	47,800
	───────	───────	───────	───────
	21,252	-	21,252	67,377
	═══════	═══════	═══════	═══════

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

4. Expenditure

Expenditure
			Total	Total
Unrestricted		Restricted	2025	2024
	£	£	£	£
Charitable activities
Staff costs	203,101	879,140	1,082,241	1,122,305
Recruitment	1,388	-	1,388	1,297
Staff training	1,643	2,162	3,805	9,179
Freelance staff/consultants	11,178	33,436	44,614	55,683
Travel and subsistence	3,395	61,037	64,432	85,722
Marketing and communications	498	38,373	38,871	30,322
Miscellaneous	11,505	638	12,143	27,865
Events and meetings	374	72,317	72,691	48,636
Support of APPGA	10,000	-	10,000	10,000
Support of Youth STOPAIDS/other donations	-	(1,054)	(1,054)	20,000
Insurance	1,212	-	1,212	1,229
Depreciation	1,449	-	1,449	1,709
Legal expenses	-	1,440	1,440	1,491
Grants payable	-	-	-	29,972
Partner payments	-	12,642	12,642	-
IT	7,941	1,769	9,710	7,675
Other office running costs	2,183	5,184	7,367	9,019
Bad debts	2,714	8,928	11,642	6,734
Reallocation for contribution to core costs	(110,024)	110,024	-	-
───────		───────	───────	───────
	148,557	1,226,036	1,374,593	1,468,838
───────		───────	───────	───────
Governance functions
Meeting and annual report costs	645	-	645	251
Audit fees	5,940	-	5,940	5,700
Other accountancy fees	3,312	-	3,312	4,478
───────		───────	───────	───────
	9,897	-	9,897	10,429
───────		───────	───────	───────
Total charitable expenditure	158,454	1,226,036	1,384,490	1,479,267
═══════		═══════	═══════	═══════

Support costs relate to the staff and running costs of the Charity’s office and are allocated on a basis consistent with the use of resources.

The Auditor fees payable are shown under governance costs above.

5. Trustees’ remuneration and expenses

The charity did not pay to its trustees any remuneration. £54 (2024: £Nil) was reimbursed to one trustee for expenses during the year.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

6. Staff costs and numbers

	2025	2024
	£	£
Salaries and wages	925,354	963,181
Social security costs	92,387	94,388
Pension	64,500	64,736
	───────	───────
	1,082,241	1,122,305
	═══════	═══════
The average number of staff employed, based on the full time equivalent,
during the period was:	18	21
	═════	═════

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

more than £60,000 is as follows:
	2025	2024
£70,001 - £80,000	1	1
£80,001 - £90,000 *	-	1
£110,001 - £120,000 *	1	-

The employees in these bands are not from STOPAIDS, but one of our hosted organisations.

The key management personnel of the charity comprise the Executive Director and the Director for Development and Engagement. The total employee benefits (including pension contributions and employer’s national insurance) of the key management personnel of the charity were £169,972 (2024: £151,182).

Total termination payments amount to £9,800 and relate to the redundancy of a hosted employee. Termination payments are recognised in expenditure when settlement agreements are reached. £Nil is included in creditors at the year end.

7. Fixed assets

Fixed assets
	Computer
	equipment	Total
	£	£
Cost
At 1 April 2024	30,295	30,295
Additions	-	-
	─────	─────
At 31 March 2025	30,295	30,295
	─────	─────
Depreciation
At 1 April 2024	26,966	26,966
Charge for the year	1,449	1,449
	─────	─────
At 31 March 2025	28,415	28,415
	─────	─────
Net book value
At 31 March 2025	1,880	1,880
	─────	─────
At 31 March 2024	3,329	3,329
	─────	─────

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

8. Debtors: amounts falling due within one year

Debtors: amounts falling due within one year
	2025	2024
	£	£
Grants and contracts receivable	1,951	23,187
Membership debtors	21,692	92,794
Other debtors	22,924	9,988
Less: provision for doubtful debts	(6,750)	-
	─────	─────
	39,817	125,969
Accrued income	64,143	145,003
	─────	─────
Total	103,960	270,972
	═════	═════

9. Creditors: amounts falling due within one year

Creditors: amounts falling due within one year
	2025	2024
	£	£
Taxation and social security	22,047	27,427
Deferred income	540,676	257,247
Sundry creditors and accruals	52,559	42,259
	─────	─────
Total	615,282	326,933
	═════	═════
Deferred income movements
Balance at 1 April 2024	257,247	395,409
Last year recognised in the year	(257,284)	(384,599)
New receipts deferred	540,713	246,437
	─────	─────
Balance at 31 March 2025	540,676	257,247
	═════	═════

Deferred income relates to the funds received from donors subject to restrictions that prevents their use until a later date.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

10. Movements in funds

Movements in funds	Movements in funds
Balance at					Balance
	1.04.24	Income	Transfers	Expenditure	31.03.25
	£	£	£	£	£
Restricted funds
APPGA	-	30,966	-	(30,966)	-
GNP+	2,965	43,692	-	(46,657)	-
Paediatric AIDS Treatment for Africa
(PATA)	-	138,687	-	(138,687)	-
Action for Global Health	140,436	88,089	-	(138,734)	89,791
Advocacy
Aidsfonds (CLSE)	-	47,983	-	(47,983)	-
New Venture Fund – Phase IV	773	114,997	-	(109,939)	5,831
Botnar Foundation	6,673	204,307	318	(204,062)	7,236
WACI Health (ACT A)	18,557	-	-	(16,937)	1,620
Warwick Policy Support	-	19,791	-	(18,905)	886
Ronald W. Naito Foundation (AfGH)	-	6,494	-	(5,104)	1,390
Unitaid 2024-26	-	40,043	-	(40,607)	(564)
The Eleanor Crook Foundation (AfGH)	-	28,233	-	(24,375)	3,858
Harm Reduction HRI
(Civil Society Alliance sub-grant)	8,854	13,107	-	(21,033)	928
The Bill and Melinda Gates
Foundation (AfGH)	19,558	195,135	-	(213,916)	777
Other
UNITAID	33,339	144,949	(719)	(168,131)	9,438
───────		───────	───────	───────	───────
	231,155	1,116,473	(401)	(1,226,036)	121,191
───────		───────	───────	───────	───────
Unrestricted funds
General	213,106	140,503	401	(159,654)	194,356
───────		───────	───────	───────	───────
Total funds	444,261	1,256,976	-	(1,385,690)	315,547
═══════		═══════	═══════	═══════	═══════

Please see Note 3 for descriptions and purposes of the Restricted Funds.

Overheads are allocated on a basis consistent with the use of resources for each of the above named projects undertaken by the Charity.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2024

10. Movements in funds (continued)

	Balance at				Balance
	1.04.23	Income	Transfers	Expenditure	31.03.24
	£	£	£	£	£
Restricted funds
APPGA	(2)	40,855	2	(40,855)	-
GNP+	2,965	96,522	-	(96,522)	2,965
Paediatric AIDS Treatment for Africa
(PATA)	-	99,251	-	(99,251)	-
Action for Global Health	145,960	98,357	(32)	(103,849)	140,436
Advocacy
New Venture Fund – Phase III	3,140	10,577	2,789	(16,506)	-
New Venture Fund – Phase IV	-	60,611	-	(59,838)	773
Botnar Foundation	3,178	181,225	(175)	(177,555)	6,673
WACI Health (ACT A)	7,805	73,422	-	(62,670)	18,557
The Wellcome Trust
(Future of GHIS)	2,679	-	(152)	(2,527)	-
Joseph Rowntree Trust	16,966	5,074	492	(22,532)	-
Love Alliance (Aidsfonds)	(5,892)	5,737	155	-	-
GNP+ (Love Alliance DH)	-	35,764	-	(35,764)	-
Health Care Advocacy International	-	31,152	-	(31,152)	-
Harm Reduction HRI
(Civil Society Alliance sub-grant)	-	18,148	-	(9,294)	8,854
Restless Development
(GenEndIt Campaign)	-	4,305	645	(4,949)	-
The Bill and Melinda
Gates Foundation	26,997	275,704	32	(283,175)	19,558
Other
UNITAID	24,601	200,919	-	(192,181)	33,339
	───────	───────	───────	───────	───────
	228,397	1,237,623	3,755	(1,238,620)	231,155
	───────	───────	───────	───────	───────
Unrestricted funds
General	251,932	205,906	(3,755)	(240,977)	213,106
	───────	───────	───────	───────	───────
Total funds	480,329	1,443,529	-	(1,479,597)	444,261
	═══════	═══════	═══════	═══════	═══════

Please see Note 3 for descriptions and purposes of the Restricted Funds.

Overheads are allocated on a basis consistent with the use of resources for each of the above named projects undertaken by the Charity.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

11. Analysis of net assets between funds

	General	Restricted	Total
	Funds	Funds	Funds
	£	£	£
Tangible fixed assets	1,880	-	1,880
Current assets	224,988	703,961	928,949
Current liabilities	(32,512)	(582,770)	(615,282)
	─────	─────	─────
Net assets at 31 March 2025	194,356	121,191	315,547
	═════	═════	═════
Tangible fixed assets	3,329	-	3,329
Current assets	266,978	500,887	767,865
Current liabilities	(57,201)	(269,732)	(326,933)
	─────	─────	─────
Net assets at 31 March 2024	213,106	231,155	444,261
	═════	═════	═════

12. Reconciliation of net movement in funds to net cash flow from operating activities

	2025	2024
	£	£
Net movement in funds	(128,714)	(36,068)
Add back depreciation	1,449	1,709
Increase in debtors	167,012	(8,590)
Decrease in creditors	288,349	(134,354)
	─────	─────
Net cash provided by operating activities	328,096	(177,303)
	═════	═════

13. Pension costs

The charity has arranged a defined contribution pension scheme managed by AVIVA (formerly Friends Provident Group plc). The charity contributes 6% of gross salary for all qualifying employees. The assets of the scheme are held separately from those of the charity. Pension costs charged in the Statement of Financial Activities represent the contributions payable by the charity in the year.

14. Related party transactions

The charity typically draws its trustees from membership organisations as standard, and as a result these entities are related parties. The membership fee charged to these organisations is at the standard rate, and there are no other specific benefits or transactions with the organisations.

During 2025, additional transactions with linked organisations were as follows:

WACI Health - Direct charitable expenditure reimbursement received: £218 WACI Health - Partner payment relating to Aidsfonds CLSE project: £6,269 (included in creditors at the year-end)

There were no other related party transactions during the period.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

15. Funds received as agent

The charity is the lead partner in the Unitaid 2024-26 project and as such received funds as agent for the sub-partner Global Health Advocates (GHA). During the year ended 31 March 2025, the charity received income amounting to £12,495 (2024: £Nil) and made disbursements of £12,495 (2024: £Nil) from this income. The balance of funds being held on behalf of GHA at the year-end amounts to £Nil (2024: £Nil) and is included in creditors. The income received and expenses paid are not included in the Statement of Financial Activities as the funds are not within the control of the charity.

STOPAIDS

Notes to the accounts (continued) for the year ended 31 March 2025

16. Comparative Statement of Financial Activities

==> picture [429 x 354] intentionally omitted <==

----- Start of picture text -----
||||| |---|---|---|---| |2024|2024|2024| |Unrestricted|Restricted|Total| |£|£|£| |Income| |Contributions from members and observers|24,576|95,358|119,934| |Grants and contracts|119,730|1,128,180|1,247,910| |Donations received|1,799|3,000|4,799| |Other income|56,292|11,085|67,377| |Interest income|3,509|-|3,509| |───────|─────── ───────| |Total|205,906|1,237,623|1,443,529| |───────|─────── ───────| |Expenditure on:| |Raising funds|330|-|330| |Charitable activities|240,647|1,238,620|1,479,267| |───────|─────── ───────| |Total|240,977|1,238,620|1,479,597| |───────|─────── ───────| |Net income/(expenditure)|(35,071)|(997)|(36,068)| |───────|─────── ───────| |Transfers between funds|(3,755)|3,755|-| |───────|─────── ───────| |Net movement in funds|(38,826)|2,758|(36,068)| |───────|─────── ───────| |Reconciliation of funds| |Total funds brought forward|251,932|228,397|480,329| |───────|─────── ───────| |Total funds carried forward|213,106|231,155|444,261| |═══════|═══════ ═══════|

----- End of picture text -----

2025-03-31-accounts

Annual Report and Accounts for Year End March 2025

Contents

Message from the CEO

ABOUT STOPAIDS

Our strategy

1. People over profit

STOPAIDS’ Anti-Oppression Framework

The framework is grounded in four key values:

The dismantling of USAID and cuts to UK ODA

Responding to the USAID cuts

Response to UK ODA Cuts Announcement

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: People over Profit

Digital health technology and human rights

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: Ensuring Enhanced Quality of Life for people living with and affected by HIV

Access to and funding for HIV services

Integration of HIV into broader physical and mental health discussions

Reduction of HIV-related structural barriers

OUR IMPACT: Major highlights between April 2024 and March 2025

Impact area: Transforming aid, solidarity and development co–operation

Sustainable Transition

Global Public Investment

Areas of work

People over profit

Ensuring Enhanced Quality of Life for people living with and affected by HIV

Meaningful integration of HIV with and access to broader physical and mental health issues / UHC

Reduction of HIV-related structural barriers

Transforming aid, solidarity and development Co-operation

Sustainable Transition

Meaningful civil society and community involvement in global health governance

Global Public Investment

Membership Engagement

Anti-Oppression Framework

A couple of examples of these experiments in action include:

Hosting and supporting networks to improve 20 collaboration and coordination

People Over Profit

Ensuring Enhanced Quality of Life for people living with and affected by HIV

Transforming aid, solidarity and development co-operation

STOPAIDS Team

Structure, governance and management

TRUSTEES

REGISTERED OFFICE:

BANKERS

PRINCIPAL OFFICERS

Governing Document

Organisational Structure

Key Management Personnel Remuneration

Risk Management

Fundraising standards information

OBJECTIVES AND ACTIVITIES

COUNTRIES BY, IN PARTICULAR BUT NOT EXCLUSIVELY:

Public Benefit Statement:

Financial review

Reserves

The Statement of trustees’ responsibilities

Independent Auditor’s Report to the members of STOPAIDS

Opinion

Basis for opinion

Conclusions relating to going concern

Other information

Opinions on other matters prescribed by the Companies Act 2006

Matters on which we are required to report by exception

Independent Auditors’ Report to the members of STOPAIDS (continued)

Matters on which we are required to report by exception (continued)

Responsibilities of trustees

Auditor’s responsibilities for the audit of the financial statements

Use of our report

STOPAIDS

Statement of Financial Activities (including Income and Expenditure Account) for the year ended 31 March 2025

STOPAIDS

Balance Sheet As at 31 March 2025

STOPAIDS

Statement of Cash Flows for the year ended 31 March 2025

STOPAIDS

Notes to the accounts for the year ended 31 March 2025

1. General information and basis of preparation

2.

(a) Basis of accounting